SPRY ARS Pharmaceuticals, Inc.companySEC Filings & Insider Trading Activity 2026
Latest ARS Pharmaceuticals, Inc. (SPRY) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 9, 2026, a 10-Q quarterly report filed on November 10, 2025, an 8-K current report filed on March 9, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for ARS Pharmaceuticals, Inc. (SPRY) (SEC CIK 1671858), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 7.01: Regulation FD Disclosure
- • Updated investor presentation filed March 9, 2026, available on company website and as Exhibit 99.2
- • Reg FD disclosure ensures all investors receive simultaneous access to the same corporate messaging
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year 2025 financial results announced March 9, 2026
- • Full detail in Exhibit 99.1 press release — key figures, guidance, and commentary found there
Recent 8-K FilingsCurrent Reports
AI-powered analysis of ARS Pharmaceuticals, Inc. (SPRY) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 9, 2026 | — | Analysis | — |
10-K | Mar 9, 2026 | Dec 31, 2025 | — | |
10-Q | Nov 10, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 13, 2025 | Jun 30, 2025 | — | |
10-Q | May 14, 2025 | Mar 31, 2025 | — | |
10-K | Mar 20, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 13, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 6, 2024 | Jun 30, 2024 | — | |
10-Q | May 9, 2024 | Mar 31, 2024 | — | |
10-K | Mar 21, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 9, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 10, 2023 | Jun 30, 2023 | — | |
10-Q | May 15, 2023 | Mar 31, 2023 | — | |
10-K | Mar 23, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 2, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 11, 2022 | Jun 30, 2022 | — | |
10-Q | May 12, 2022 | Mar 31, 2022 | — | |
10-K | Mar 31, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 10, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 12, 2021 | Jun 30, 2021 | — | |
10-Q | May 13, 2021 | Mar 31, 2021 | — | |
10-K | Mar 29, 2021 | Dec 31, 2020 | — |
Frequently Asked Questions
What are the latest SPRY SEC filings in 2026?
ARS Pharmaceuticals, Inc. (SPRY) has filed a 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 10, 2025, an 8-K current report on March 9, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did SPRY file its most recent 10-K annual report?
ARS Pharmaceuticals, Inc. (SPRY) filed its most recent 10-K annual report on March 9, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view SPRY 10-Q quarterly reports?
ARS Pharmaceuticals, Inc. (SPRY)'s most recent 10-Q quarterly report was filed on November 10, 2025. SignalX displays every SPRY 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has SPRY filed recently?
ARS Pharmaceuticals, Inc. (SPRY)'s most recent 8-K was filed on March 9, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find SPRY insider trading activity (Form 4)?
SignalX aggregates every SPRY Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does SPRY file with the SEC?
ARS Pharmaceuticals, Inc. (SPRY) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new SPRY filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for ARS Pharmaceuticals, Inc. (SPRY).
What is SPRY's SEC CIK number?
ARS Pharmaceuticals, Inc. (SPRY)'s SEC CIK (Central Index Key) number is 1671858. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1671858 to look up all SPRY filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find SPRY return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from ARS Pharmaceuticals, Inc. (SPRY) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of ARS Pharmaceuticals, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 22+ filings.